Abstract 0874: At wk16, deucravacitinib (vs placebo) showed greater efficacy in multiple #PsA disease activity measures 🔹 ↑ MDA, DAPSA LDA/remission, and PsARC responses 🔹 Greater ↓in PASDAS and mCPDAI 🔹 Benefits seen in both men and women @RheumNow #ACR25